Prosecution Insights
Last updated: November 12, 2026

BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, ensuring that each case is reviewed by a different individual. The prosecution is also taking place in 2 distinct art units, which indicates that the company's pharmaceutical filings are technically diverse enough to be handled by different specialized groups. This distribution suggests a broad approach to securing intellectual property in the biotech sector.

The busiest examiner for this portfolio is CUTLIFF, YATE KAI RENE, who is responsible for 1 busiest examiner pending office action. With a total of 2 pending office actions, this examiner handles a significant portion of the company's current active cases. This concentration means that the examiner's feedback will be a major factor in the portfolio's overall progress. For a practitioner, managing 2 distinct examiners across 2 distinct art units requires a strategy that can accommodate different examining styles and procedural norms. The outcome of these 2 pending office actions will provide important insights into the company's standing within the Biotechnology & Pharmaceuticals field.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CUTLIFF, YATE KAI RENE 1 79.9% +24.2%
BRANDSEN, BENJAMIN MICHAEL 1 61.9% +20.6%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18684974 AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE CUTLIFF, YATE KAI RENE —
18288402 SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD BRANDSEN, BENJAMIN MICHAEL —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18684974 AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE CUTLIFF, YATE KAI RENE —
18288402 SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD BRANDSEN, BENJAMIN MICHAEL —

Top Art Units

Art UnitApps
1692 1
1693 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18684974 AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE CUTLIFF, YATE KAI RENE 1692 §102§103§112 Non-Final OA — Pending Feb 20, 2024
18288402 SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD BRANDSEN, BENJAMIN MICHAEL 1693 §103§112 Final Rejection — Pending Oct 26, 2023

Managing BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. have?

BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. applications?

Yate Kai Rene Cutliff has the most, with 1 of BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.'s pending office actions.

What technology area are BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month